A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon (R)) as a structure modifying therapy in osteoarthritis of the hip and knee

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F00%3A%230000956" target="_blank" >RIV/00064190:_____/00:#0000956 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1053/joca.1999.0307" target="_blank" >http://dx.doi.org/10.1053/joca.1999.0307</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1053/joca.1999.0307" target="_blank" >10.1053/joca.1999.0307</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon (R)) as a structure modifying therapy in osteoarthritis of the hip and knee

Popis výsledku v původním jazyce

To determine the structure (disease) modifying effect of a glycosaminoglycan polypeptide association complex (GP-C; Rumalon(R)) in patients with knee and hip osteoarthritis (OA). Methods: Double-blind, randomized, placebo-controlled five-year study. Primary assessment criterion was change in radiographic joint space width between baseline and follow-up at 5 years. Secondary outcome criteria included Lequesne algofunctional index (LAI), pain on passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of placebo or GP-C 2 mi intramuscularly in 5 years (two courses each year). Each course included 15 injections administered twice weekly. Results: There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-G treated groups were comparable as to sex, age, duration of disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37+/-0.08 (mean+/-standard

Název v anglickém jazyce

A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon (R)) as a structure modifying therapy in osteoarthritis of the hip and knee

Popis výsledku anglicky

To determine the structure (disease) modifying effect of a glycosaminoglycan polypeptide association complex (GP-C; Rumalon(R)) in patients with knee and hip osteoarthritis (OA). Methods: Double-blind, randomized, placebo-controlled five-year study. Primary assessment criterion was change in radiographic joint space width between baseline and follow-up at 5 years. Secondary outcome criteria included Lequesne algofunctional index (LAI), pain on passive motion and consumption of non-steroidal antiinflammatory drugs (NSAIDs). The patients received 10 courses of injections of placebo or GP-C 2 mi intramuscularly in 5 years (two courses each year). Each course included 15 injections administered twice weekly. Results: There were 277 patients with knee OA and 117 patients with hip OA. Control and GP-G treated groups were comparable as to sex, age, duration of disease, body weight, X-ray stage and value of LAI at the baseline. Knee joint space at 5 years decreased 0.37+/-0.08 (mean+/-standard

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2000

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

OSTEOARTHRITIS AND CARTILAGE

ISSN

1063-4584

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

335-342

Kód UT WoS článku

000089316600002

EID výsledku v databázi Scopus

—